These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2655530)

  • 41. In vitro activity of L-627, a new carbapenem.
    Catchpole CR; Wise R; Thornber D; Andrews JM
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1928-34. PubMed ID: 1416883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin.
    Chin NX; Neu HC
    Chemioterapia; 1986 Apr; 5(2):92-100. PubMed ID: 3518967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627.
    Yoshida M; Mitsuhashi S
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):625-9. PubMed ID: 2209630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y; Sunagawa M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem.
    Asahi Y; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1995 May; 39(5):1030-7. PubMed ID: 7625784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1990; 13(1):57-61. PubMed ID: 2331851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.
    Sanders CC; Sanders WE; Thomson KS; Iaconis JP
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():187-96. PubMed ID: 2808207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
    Piddock LJ; Turner HL
    Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1186-91. PubMed ID: 1291320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
    Zerva L; Biedenbach DJ; Jones RN
    J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of CGP 31608, a new penem.
    Wise R; Andrews JM; Piddock LJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):267-73. PubMed ID: 3105451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antibacterial activity of panipenem against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):808-26. PubMed ID: 12621735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.